Published on 22/12/2025
Best Practices for Conducting Multi-Regional Clinical Trials in China
Introduction
China’s inclusion in multi-regional clinical trials (MRCTs) has become a strategic priority for global sponsors. With a vast patient population, expanding trial infrastructure, and regulatory reforms under the National Medical Products Administration (NMPA), China now plays a central role in global clinical development. The adoption of the International Council for Harmonisation (ICH) E17 guideline has further aligned China with international MRCT practices, allowing data generated in Chinese sites to be integrated into global submissions. However, successful MRCT execution in China requires careful planning to address regulatory, operational, and cultural considerations. This article explores best practices for sponsors, CROs, and investigators conducting MRCTs that include China.
Background and Regulatory Framework
China’s MRCT Evolution
Historically, sponsors excluded China from MRCTs due to long approval timelines, limited site capacity, and concerns about data quality. This often necessitated bridging studies, delaying patient access. With reforms since 2017, including the silent IND approval system and site accreditation expansion, China is now a key MRCT participant.
ICH E17 Implementation
The NMPA formally adopted ICH E17 in 2019, providing guidance on MRCT design, patient allocation, and regional subgroup analyses. Sponsors must justify Chinese patient enrollment numbers,
Case Example: Cardiovascular MRCT
A global cardiovascular trial included 800 patients from Chinese hospitals. By aligning protocols with NMPA and ICH E17, the sponsor integrated Chinese data into FDA and EMA submissions, avoiding a separate bridging study and expediting global approvals.
Core Clinical Trial Insights
Regulatory Engagement with NMPA
Early engagement with the NMPA is critical. Sponsors should conduct pre-IND consultations to clarify Chinese patient enrollment expectations, protocol adaptations, and data localization requirements. Mid-trial consultations help resolve operational issues and maintain compliance.
Site Selection and Readiness
Tier-1 hospitals in major cities are preferred for MRCTs due to infrastructure, experienced investigators, and established QA systems. Expanding into Tier-2 hospitals increases patient diversity but requires additional training and CRO support. Site feasibility assessments should include ethics committee capacity and prior MRCT experience.
Patient Recruitment and Diversity
Recruiting representative Chinese patients is crucial for global data acceptance. Sponsors must avoid overrepresentation of urban populations and engage rural hospitals to ensure diversity. Collaborations with patient advocacy groups improve recruitment in rare diseases and oncology trials.
Data Integration and Standardization
Data generated in Chinese sites must align with global standards such as CDISC for seamless integration. Translation of CRFs, SAE reports, and informed consent forms requires certified processes to ensure accuracy. CROs often manage bilingual data harmonization.
Operational Role of CROs
CROs provide vital support for MRCTs, including site training, ethics submissions, pharmacovigilance, and inspection readiness. Sponsors often use hybrid models, combining global CRO oversight with local Chinese CRO expertise to ensure compliance and operational efficiency.
Inspection Readiness
The NMPA conducts GCP inspections of MRCT sites, focusing on informed consent, data integrity, and TMF completeness. Sponsors must conduct mock audits and ensure sites are prepared for both NMPA and global regulator inspections (FDA, EMA).
Best Practices & Preventive Measures
Sponsors should:
✔️ Engage NMPA early for protocol and patient enrollment guidance
✔️ Select sites based on MRCT readiness and ethics capacity
✔️ Implement bilingual systems for CRFs and TMFs
✔️ Train investigators in ICH E17 MRCT principles
✔️ Partner with CROs for operational support and inspections
✔️ Monitor recruitment diversity to meet global regulatory expectations
These practices ensure successful integration of Chinese data into global MRCTs.
Scientific & Regulatory Evidence
China’s MRCT framework reflects ICH E17 principles, ICH E6(R2) GCP, and WHO MRCT guidance. Evidence shows that Chinese MRCT participation accelerates global approvals and improves representativeness of Asian populations. Comparative analysis with FDA and EMA expectations confirms convergence in MRCT standards.
Special Considerations
Rare disease and pediatric MRCTs in China face unique challenges, including small patient pools and complex ethical considerations. Sponsors must design flexible recruitment strategies and obtain HGRAC approval for genetic studies, ensuring compliance with national policies on human genetic resources.
When Sponsors Should Seek Regulatory Advice
Sponsors should seek regulatory advice from the NMPA during MRCT design, especially regarding Chinese patient enrollment numbers, protocol adaptations, and data localization. Early consultations reduce risks of rejection and facilitate smooth integration of Chinese data into multinational submissions.
Case Studies
Case Study 1: Oncology MRCT with Biomarker Focus
A global oncology sponsor included 600 Chinese patients in a biomarker-driven MRCT. By aligning biomarker assay validation with NMPA and global standards, the sponsor ensured acceptance of Chinese data by the FDA and EMA, expediting simultaneous approvals.
Case Study 2: Rare Disease MRCT Adaptation
A rare disease MRCT struggled with recruitment in China due to small patient populations. The sponsor partnered with patient advocacy groups and expanded into Tier-2 hospitals, ultimately achieving enrollment targets and data acceptance in global submissions.
FAQs
1. Why is China important in MRCTs?
China offers large patient populations, regulatory alignment with ICH E17, and global acceptance of data, reducing the need for bridging studies.
2. How does the NMPA support MRCTs?
The NMPA provides expedited IND reviews, guidance on protocol design, and alignment with ICH standards for multinational submissions.
3. What are common challenges in Chinese MRCTs?
Challenges include site readiness, language translation, data localization, and ensuring patient diversity across urban and rural populations.
4. How can sponsors ensure data integration?
By using CDISC standards, bilingual CRFs, and CRO-managed harmonization processes to align Chinese data with global datasets.
5. What role do CROs play in MRCTs?
CROs provide operational expertise, site training, regulatory submissions, and inspection readiness support for multinational sponsors.
6. How do Chinese MRCTs compare globally?
China’s MRCT practices now closely align with FDA and EMA requirements, reflecting global harmonization under ICH E17.
Conclusion & Call-to-Action
China’s integration into MRCTs has transformed the global clinical research landscape. With regulatory reforms, ICH E17 adoption, and expanding hospital networks, Chinese sites are now critical for multinational trial success. Sponsors must invest in regulatory engagement, site readiness, and bilingual data integration to ensure seamless inclusion of China in MRCTs. Organizations planning global trials should adopt best practices outlined here to maximize efficiency, accelerate approvals, and expand patient access worldwide.